Skip to main content
Caplight Logo









LevitasBio

LevitasBio

Private
Hayward, CaliforniaHealthcare & Life Scienceshttps://levitasbio.com/

Last Round

Series C

Nov 7, 2022

Total Funding Raised

$61M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

LevitasBio is a life sciences company that provides a label-free single-cell imaging and profiling platform for purifying cells and nuclei without markers or modifications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS, Services & Consulting

AI Layer

Non-AI

Keywords

cell isolationcell enrichmentlabel-free cell sortingfluorescence-activated cell sortingFACSsingle-cell analysisbiotech equipmentlevitation technologycell therapy developmenttissue dissociationbenchtop lab equipmentrazor and blades modelsample preparationmagnetic bead separationlab automation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

LevitasBio Comparables

Compare LevitasBio with similar companies based on industry and business-model similarity.

LevitasBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Deepcell
84%
NanoCellect Biomedical
84%
Cell Microsystems
82%

LevitasBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 7, 2022
Series BJan 6, 2021
Series AAug 3, 2017

Key People

Founding team and executive leadership

Martin Pieprzyk

Chief Executive Officer

Executive Team

LevitasBio Investors

Notable investors and investment history

LevitasBio investors
InvestorRounds
Wuhan Thalys Medical TechnologySeries B
Pavilion CapitalSeries C
Novalis LifeSciencesSeries C
EosSeries C
Decheng CapitalSeries C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 51% MoM.

  • Nov 7, 2022

    $35M round led by Novalis LifeSciences.

LevitasBio Filings

Explore SEC and related filing metadata, where available.

LevitasBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about LevitasBio's valuation, stock price, and market status.

Is LevitasBio a public or private company?

LevitasBio is a private company.

What is the current stock price of LevitasBio?

LevitasBio is a private company with no public stock price. No recent secondary market data is available.

How much is LevitasBio worth (valuation)?

Valuation information for LevitasBio is not publicly available.

Can I buy LevitasBio stock?

LevitasBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was LevitasBio's last funding round?

LevitasBio's most recent funding round was Series C on November 7, 2022.

Who are the main investors in LevitasBio?

Key investors in LevitasBio include Novalis LifeSciences, Decheng Capital.

Will LevitasBio IPO soon?

No public IPO plans have been announced for LevitasBio.

How can I track LevitasBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LevitasBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHayward, California
Employee Range25
Year Founded2017
Last FundingNov 7, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?